ILLUMINA INC (ILU.DE) Stock Fundamental Analysis

FRA:ILU • US4523271090

95.79 EUR
-3.69 (-3.71%)
Last: Feb 12, 2026, 07:00 PM
Fundamental Rating

5

ILU gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 21 industry peers in the Life Sciences Tools & Services industry. ILU has an excellent financial health rating, but there are some minor concerns on its profitability. ILU has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • In the past year ILU was profitable.
  • In the past year ILU had a positive cash flow from operations.
  • In the past 5 years ILU reported 4 times negative net income.
  • Of the past 5 years ILU 4 years had a positive operating cash flow.
ILU.DE Yearly Net Income VS EBIT VS OCF VS FCFILU.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B -1B -2B -3B -4B

1.2 Ratios

  • With an excellent Return On Assets value of 11.38%, ILU belongs to the best of the industry, outperforming 95.24% of the companies in the same industry.
  • With an excellent Return On Equity value of 29.53%, ILU belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
  • With an excellent Return On Invested Capital value of 14.61%, ILU belongs to the best of the industry, outperforming 95.24% of the companies in the same industry.
Industry RankSector Rank
ROA 11.38%
ROE 29.53%
ROIC 14.61%
ROA(3y)-22.28%
ROA(5y)-10.63%
ROE(3y)-46.16%
ROE(5y)-23.48%
ROIC(3y)N/A
ROIC(5y)N/A
ILU.DE Yearly ROA, ROE, ROICILU.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40 -60

1.3 Margins

  • Looking at the Profit Margin, with a value of 16.39%, ILU belongs to the top of the industry, outperforming 85.71% of the companies in the same industry.
  • ILU's Operating Margin of 20.41% is amongst the best of the industry. ILU outperforms 85.71% of its industry peers.
  • In the last couple of years the Operating Margin of ILU has declined.
  • ILU has a better Gross Margin (66.74%) than 100.00% of its industry peers.
  • In the last couple of years the Gross Margin of ILU has remained more or less at the same level.
Industry RankSector Rank
OM 20.41%
PM (TTM) 16.39%
GM 66.74%
OM growth 3YN/A
OM growth 5Y-11.47%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.07%
GM growth 5Y-1.23%
ILU.DE Yearly Profit, Operating, Gross MarginsILU.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

7

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), ILU is creating some value.
  • ILU has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ILU.DE Yearly Shares OutstandingILU.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
ILU.DE Yearly Total Debt VS Total AssetsILU.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.2 Solvency

  • An Altman-Z score of 3.91 indicates that ILU is not in any danger for bankruptcy at the moment.
  • ILU has a Altman-Z score of 3.91. This is in the better half of the industry: ILU outperforms 76.19% of its industry peers.
  • ILU has a debt to FCF ratio of 1.99. This is a very positive value and a sign of high solvency as it would only need 1.99 years to pay back of all of its debts.
  • ILU has a better Debt to FCF ratio (1.99) than 100.00% of its industry peers.
  • ILU has a Debt/Equity ratio of 0.42. This is a healthy value indicating a solid balance between debt and equity.
  • ILU has a better Debt to Equity ratio (0.42) than 85.71% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.42
Debt/FCF 1.99
Altman-Z 3.91
ROIC/WACC1.37
WACC10.65%
ILU.DE Yearly LT Debt VS Equity VS FCFILU.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B 6B 8B 10B

2.3 Liquidity

  • ILU has a Current Ratio of 1.43. This is a normal value and indicates that ILU is financially healthy and should not expect problems in meeting its short term obligations.
  • ILU has a Current ratio of 1.43. This is comparable to the rest of the industry: ILU outperforms 57.14% of its industry peers.
  • A Quick Ratio of 1.12 indicates that ILU should not have too much problems paying its short term obligations.
  • ILU has a better Quick ratio (1.12) than 71.43% of its industry peers.
Industry RankSector Rank
Current Ratio 1.43
Quick Ratio 1.12
ILU.DE Yearly Current Assets VS Current LiabilitesILU.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

4

3. Growth

3.1 Past

  • ILU shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 97.96%, which is quite impressive.
  • The Earnings Per Share has been growing slightly by 1.51% on average over the past years.
EPS 1Y (TTM)97.96%
EPS 3Y31.77%
EPS 5Y1.51%
EPS Q2Q%56.98%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%4.98%

3.2 Future

  • ILU is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.42% yearly.
  • ILU is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.54% yearly.
EPS Next Y6.75%
EPS Next 2Y10.5%
EPS Next 3Y9.64%
EPS Next 5Y11.42%
Revenue Next Year2.81%
Revenue Next 2Y4.54%
Revenue Next 3Y4.65%
Revenue Next 5Y5.54%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
ILU.DE Yearly Revenue VS EstimatesILU.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B
ILU.DE Yearly EPS VS EstimatesILU.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2 4 6 8 10

4

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 23.48, which indicates a rather expensive current valuation of ILU.
  • ILU's Price/Earnings ratio is in line with the industry average.
  • ILU is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 27.67, which is the current average of the S&P500 Index.
  • A Price/Forward Earnings ratio of 21.97 indicates a rather expensive valuation of ILU.
  • ILU's Price/Forward Earnings ratio is in line with the industry average.
  • The average S&P500 Price/Forward Earnings ratio is at 27.69. ILU is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 23.48
Fwd PE 21.97
ILU.DE Price Earnings VS Forward Price EarningsILU.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ILU indicates a somewhat cheap valuation: ILU is cheaper than 61.90% of the companies listed in the same industry.
  • Based on the Price/Free Cash Flow ratio, ILU is valued cheaply inside the industry as 85.71% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 17.38
EV/EBITDA 15.54
ILU.DE Per share dataILU.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15 20

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • ILU has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)3.48
PEG (5Y)15.56
EPS Next 2Y10.5%
EPS Next 3Y9.64%

0

5. Dividend

5.1 Amount

  • ILU does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

ILLUMINA INC

FRA:ILU (2/12/2026, 7:00:00 PM)

95.79

-3.69 (-3.71%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-05
Earnings (Next)05-06
Inst Owners104.7%
Inst Owner ChangeN/A
Ins Owners0.17%
Ins Owner ChangeN/A
Market Cap14.64B
Revenue(TTM)N/A
Net Income(TTM)703.00M
Analysts73.33
Price Target114.99 (20.04%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.9%
Min EPS beat(2)12.52%
Max EPS beat(2)15.27%
EPS beat(4)3
Avg EPS beat(4)5.34%
Min EPS beat(4)-7.76%
Max EPS beat(4)15.27%
EPS beat(8)6
Avg EPS beat(8)97.15%
EPS beat(12)10
Avg EPS beat(12)231.96%
EPS beat(16)13
Avg EPS beat(16)178.01%
Revenue beat(2)0
Avg Revenue beat(2)-0.74%
Min Revenue beat(2)-1.21%
Max Revenue beat(2)-0.28%
Revenue beat(4)0
Avg Revenue beat(4)-0.66%
Min Revenue beat(4)-1.21%
Max Revenue beat(4)-0.18%
Revenue beat(8)3
Avg Revenue beat(8)-0.29%
Revenue beat(12)4
Avg Revenue beat(12)-0.57%
Revenue beat(16)5
Avg Revenue beat(16)-0.78%
PT rev (1m)7.13%
PT rev (3m)15.93%
EPS NQ rev (1m)0.77%
EPS NQ rev (3m)0.25%
EPS NY rev (1m)0.24%
EPS NY rev (3m)1.57%
Revenue NQ rev (1m)0.09%
Revenue NQ rev (3m)-0.18%
Revenue NY rev (1m)0.02%
Revenue NY rev (3m)0.23%
Valuation
Industry RankSector Rank
PE 23.48
Fwd PE 21.97
P/S 4.05
P/FCF 17.38
P/OCF 15.49
P/B 7.3
P/tB 16.66
EV/EBITDA 15.54
EPS(TTM)4.08
EY4.26%
EPS(NY)4.36
Fwd EY4.55%
FCF(TTM)5.51
FCFY5.75%
OCF(TTM)6.18
OCFY6.46%
SpS23.63
BVpS13.12
TBVpS5.75
PEG (NY)3.48
PEG (5Y)15.56
Graham Number34.71
Profitability
Industry RankSector Rank
ROA 11.38%
ROE 29.53%
ROCE 20.76%
ROIC 14.61%
ROICexc 20.97%
ROICexgc 38.52%
OM 20.41%
PM (TTM) 16.39%
GM 66.74%
FCFM 23.32%
ROA(3y)-22.28%
ROA(5y)-10.63%
ROE(3y)-46.16%
ROE(5y)-23.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y-6.48%
ROICexc growth 3YN/A
ROICexc growth 5Y-9.28%
OM growth 3YN/A
OM growth 5Y-11.47%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.07%
GM growth 5Y-1.23%
F-Score7
Asset Turnover0.69
Health
Industry RankSector Rank
Debt/Equity 0.42
Debt/FCF 1.99
Debt/EBITDA 0.86
Cap/Depr 44.36%
Cap/Sales 2.85%
Interest Coverage 250
Cash Conversion 97.57%
Profit Quality 142.25%
Current Ratio 1.43
Quick Ratio 1.12
Altman-Z 3.91
F-Score7
WACC10.65%
ROIC/WACC1.37
Cap/Depr(3y)66.6%
Cap/Depr(5y)76.75%
Cap/Sales(3y)5.82%
Cap/Sales(5y)5.58%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)97.96%
EPS 3Y31.77%
EPS 5Y1.51%
EPS Q2Q%56.98%
EPS Next Y6.75%
EPS Next 2Y10.5%
EPS Next 3Y9.64%
EPS Next 5Y11.42%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%4.98%
Revenue Next Year2.81%
Revenue Next 2Y4.54%
Revenue Next 3Y4.65%
Revenue Next 5Y5.54%
EBIT growth 1Y154.36%
EBIT growth 3YN/A
EBIT growth 5Y-7.67%
EBIT Next Year37.12%
EBIT Next 3Y17.25%
EBIT Next 5Y16.22%
FCF growth 1Y495.24%
FCF growth 3Y28.14%
FCF growth 5Y-3.38%
OCF growth 1Y179.8%
OCF growth 3Y15.37%
OCF growth 5Y-4.45%

ILLUMINA INC / ILU.DE FAQ

What is the ChartMill fundamental rating of ILLUMINA INC (ILU.DE) stock?

ChartMill assigns a fundamental rating of 5 / 10 to ILU.DE.


What is the valuation status for ILU stock?

ChartMill assigns a valuation rating of 4 / 10 to ILLUMINA INC (ILU.DE). This can be considered as Fairly Valued.


How profitable is ILLUMINA INC (ILU.DE) stock?

ILLUMINA INC (ILU.DE) has a profitability rating of 6 / 10.


Can you provide the financial health for ILU stock?

The financial health rating of ILLUMINA INC (ILU.DE) is 7 / 10.